Induction of cuproptosis and targeting of multiple signaling pathways show promising applications in tumor therapy. In this study, we synthesized two thiosemicarbazone-copper complexes ([Cu(L)Cl] 1 and [CuCu(L)Cl] 2, where HL is the ()--methyl-2-(phenyl(pyridin-2-yl)methylene ligand), to assess their antilung cancer activities. Both copper complexes showed better anticancer activity than cisplatin and exhibited hemolysis comparable to that of cisplatin.
View Article and Find Full Text PDFSpectrochim Acta A Mol Biomol Spectrosc
January 2019
Developing high performance fluorescent chemo-sensors for in vitro and in vivo Al detection is highly desirable, because Al accumulation has been involved to various diseases. Herein, we report a highly selective and sensitive Schiff base fluorescent probe, HL, based on 2-hydroxynaphthalene, which can recognize aluminum ions and exhibit an "off-on" mode with high selectivity in methanol solutions. The detection limit of the probe for Al is as low as 10 M which was determined by fluorescent titration.
View Article and Find Full Text PDFThiazolidinone derivatives have been previously shown significant anti-cancer activities. Two amino-thiazolidinone complexes, [Pt(HTone)Cl] (1) and [Cu(HTone)Cl] (3) (HTone = (Z)-2-((E)-(1-(pyridin-2-yl)ethylidene)hydrazono)thiazolidin-4-one) and one ethyl-modified [Pt(ETone)Cl] (2) (ETone = (Z)-3-ethyl-2-((E)-(1-(pyridin-2-yl)ethylidene) hydrazono)thiazolidin-4-one)], were designed and synthesized in order to explore novel metal-based antitumor agents. MTT assay indicated that 1 and 3 were markedly cytotoxic to MCF-7, HepG-2 and NCI-H460 tumor cells, superior to both cisplatin and the HTone ligand.
View Article and Find Full Text PDFAberrant ribosome biogenesis and enlarged nucleoli have long been used by pathologists as a marker of aggressive tumors. Suppression of RNA polymerase I (Pol I) transcription machinery within the nucleolus could be a direct way to trigger the nucleolar stress and to inhibit the rapid proliferation of cancer cells. Here we modified cisplatin with an analogue of the selective inhibitor of RNA polymerase I-mediated transcription BMH-21 to develop a novel platinum-based Pol I selective inhibitor.
View Article and Find Full Text PDF